Literature DB >> 22843882

Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study.

Stefan Hauser1, Monika Kogej, Guido Fechner, Alexander Von Ruecker, Patrick J Bastian, Jochen Von Pezold, Roland Vorreuther, Gerd Lümmen, Stefan C Müller, Jörg Ellinger.   

Abstract

BACKGROUND/AIM: Cell-free DNA may serve as a biomarker for patients with cancer; we designed our study to determine its potential in patients with bladder cancer (BCA).
MATERIALS AND METHODS: Short β-actin (ACTB)-106 and large ACTB-384 fragments were quantified using real time PCR (RT-PCR); the ratio of ACTB-384/ACTB-106 was defined as DNA integrity. We analyzed the serum from 95 patients with and from 132 without BCA.
RESULTS: Patients with BCA had increased ACTB-106 levels and lower DNA integrity compared to patients without cancer. However, patients undergoing transurethral bladder resection (TURB) with histological exclusion of BCA had a similar ACTB-106 level and DNA integrity, as patients with BCA. Cell-free DNA was not correlated with smoker status, pT stage, grade or lymph node metastasis, or DNA integrity. There was a weak inverse correlation of age with DNA integrity in patients with BCA.
CONCLUSION: Analysis of serum cell-free DNA levels and fragmentation patterns are of limited value regarding the identification of patients with BCA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843882

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer: a meta-analysis.

Authors:  Xin-Shuai Wang; Meng-Qi Zhao; Li Zhang; De-Jiu Kong; Xue-Zhen Ding; Xiao-Chen Hu; Jun-Qiang Yang; She-Gan Gao
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

Review 2.  Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers.

Authors:  Björn L D M Brücher; Yan Li; Philipp Schnabel; Martin Daumer; Timothy J Wallace; Rainer Kube; Bruno Zilberstein; Scott Steele; Jan L A Voskuil; Ijaz S Jamall
Journal:  Clin Transl Med       Date:  2016-04-06

Review 3.  The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.

Authors:  Sabine Riethdorf; Armin Soave; Michael Rink
Journal:  Transl Androl Urol       Date:  2017-12

4.  Temporal patterns of circulating cell-free DNA (cfDNA) in a newborn piglet model of perinatal asphyxia.

Authors:  Sophia Manueldas; Torkil Benterud; Corina Silvia Rueegg; Håvard Tetlie Garberg; Marianne Ullestad Huun; Leonid Pankratov; Monica Åsegg-Atneosen; Rønnaug Solberg; Javier Escobar; Ola Didrik Saugstad; Lars Oliver Baumbusch
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

Review 5.  Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond.

Authors:  Yu-Ru Liu; Carlos J Ortiz-Bonilla; Yi-Fen Lee
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.